Regeneron Pharmaceuticals, Inc. $REGN Stock Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,865 shares of the biopharmaceutical company’s stock after purchasing an additional 656 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Regeneron Pharmaceuticals were worth $2,306,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $5,682,636,000. State Street Corp grew its position in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Bank of America Corp DE grew its position in Regeneron Pharmaceuticals by 8.5% during the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock valued at $805,023,000 after buying an additional 101,469 shares during the period. Amundi grew its position in shares of Regeneron Pharmaceuticals by 0.4% in the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock valued at $631,983,000 after purchasing an additional 3,742 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $473,872,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research note on Monday, November 2nd. Truist Financial upped their price target on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Cantor Fitzgerald increased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. Finally, Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the stock an “equal weight” rating in a research report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $904.35 on Friday. The firm has a 50 day simple moving average of $804.38 and a 200 day simple moving average of $742.81. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $991.73. The stock has a market cap of $93.11 billion, a P/E ratio of 19.97, a P/E/G ratio of 1.51 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the prior year, the firm earned $11.83 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 36.3% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 7,830 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the sale, the director owned 5,219 shares in the company, valued at $5,057,680.71. This represents a 60.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $900.00, for a total value of $360,000.00. Following the transaction, the director owned 603 shares in the company, valued at $542,700. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 28,228 shares of company stock worth $25,985,950 over the last ninety days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.